. home.aspx



Novo Holdings invests in three more AMR biotechs

January 22, 2019 / George Underwood

Novo Holdings’ REPAIR Impact Fund, which helps fund companies tackling antimicrobial resistance (AMR), has announced three new investments. The first beneficiary is AstraZeneca spin-off Entasis Therapeutics, whose programmes include a new class of non-β-lactam PBP inhibitors (NBP) targeting multi-resistant Pseudomonas aeruginosa infections. The REPAIR Fund participated in the $75 million NASDAQ listing in September 2018 by investing $10 million. A report published last year named Entasis as the most active biotech in AMR R&D.
Novo Holdings also invested a further €3.6 million into Danish company Minervax, a Lund University spin-out developing a prophylactic vaccine against Group B Streptococcus (GBS), responsible for 50% of life-threatening infections in newborns, as well as stillbirths and preterm deliveries in pregnant women. Finally, UK-based Procarta Biosystems has received €1.5 million from the Fund. Procarta is developing a pipeline of antibacteria...